zynex inc - ZYXI

ZYXI

Close Chg Chg %
0.86 -0.12 -14.20%

Closed Market

0.74

-0.12 (14.20%)

Volume: 791.86K

Last Updated:

Dec 12, 2025, 4:00 PM EDT

Company Overview: zynex inc - ZYXI

ZYXI Key Data

Open

$0.88

Day Range

0.74 - 0.88

52 Week Range

0.38 - 8.72

Market Cap

$26.44M

Shares Outstanding

30.39M

Public Float

15.82M

Beta

1.00

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$2.43

Yield

0.00%

Dividend

$0.10

EX-DIVIDEND DATE

Jan 5, 2022

SHORT INTEREST

N/A

AVERAGE VOLUME

14.16M

 

ZYXI Performance

1 Week
 
-16.85%
 
1 Month
 
30.26%
 
3 Months
 
-50.00%
 
1 Year
 
-90.91%
 
5 Years
 
-94.71%
 

ZYXI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About zynex inc - ZYXI

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. It also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

ZYXI At a Glance

Zynex, Inc.
9655 Maroon Circle
Englewood, Colorado 80112
Phone 1-800-495-6670 Revenue 192.35M
Industry Medical Specialties Net Income 2.99M
Sector Health Technology 2024 Sales Growth 4.358%
Fiscal Year-end 12 / 2025 Employees 1,000
View SEC Filings

ZYXI Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 86.408
Price to Sales Ratio 1.345
Price to Book Ratio 7.151
Price to Cash Flow Ratio 20.34
Enterprise Value to EBITDA 27.192
Enterprise Value to Sales 1.523
Total Debt to Enterprise Value 0.252

ZYXI Efficiency

Revenue/Employee 192,354.00
Income Per Employee 2,994.00
Receivables Turnover 10.673
Total Asset Turnover 1.44

ZYXI Liquidity

Current Ratio 4.458
Quick Ratio 3.633
Cash Ratio 2.35

ZYXI Profitability

Gross Margin 79.502
Operating Margin 3.114
Pretax Margin 1.886
Net Margin 1.557
Return on Assets 2.241
Return on Equity 7.317
Return on Total Capital 2.733
Return on Invested Capital 2.678

ZYXI Capital Structure

Total Debt to Total Equity 206.744
Total Debt to Total Capital 67.399
Total Debt to Total Assets 58.542
Long-Term Debt to Equity 194.654
Long-Term Debt to Total Capital 63.458
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Zynex Inc - ZYXI

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
130.30M 158.17M 184.32M 192.35M
Sales Growth
+62.63% +21.39% +16.54% +4.36%
Cost of Goods Sold (COGS) incl D&A
27.32M 32.01M 38.37M 39.43M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.68M 3.93M 4.22M 4.78M
Depreciation
3.66M 3.00M 2.68M 2.90M
Amortization of Intangibles
25.00K 930.00K 1.54M 1.88M
COGS Growth
+56.86% +17.14% +19.88% +2.77%
Gross Income
102.98M 126.16M 145.96M 152.93M
Gross Income Growth
+64.23% +22.51% +15.69% +4.77%
Gross Profit Margin
+79.03% +79.77% +79.19% +79.50%
2021 2022 2023 2024 5-year trend
SG&A Expense
80.61M 103.22M 135.18M 146.94M
Research & Development
2.60M 7.10M 9.20M 12.00M
Other SG&A
78.01M 96.12M 125.98M 134.94M
SGA Growth
+53.68% +28.05% +30.95% +8.70%
Other Operating Expense
- - - -
-
Unusual Expense
- - 300.00K (2.85M)
-
EBIT after Unusual Expense
22.37M 22.64M 13.63M 5.99M
Non Operating Income/Expense
- - 39.00K 19.00K
-
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
95.00K 440.00K 1.09M 2.38M
Interest Expense Growth
+400.00% +363.16% +148.64% +117.73%
Gross Interest Expense
95.00K 440.00K 1.09M 2.38M
Interest Capitalized
- - - -
-
Pretax Income
22.27M 22.20M 12.58M 3.63M
Pretax Income Growth
+119.35% -0.33% -43.33% -71.17%
Pretax Margin
+17.09% +14.03% +6.82% +1.89%
Income Tax
5.17M 5.15M 2.85M 633.00K
Income Tax - Current - Domestic
5.31M 6.00M 5.15M 1.57M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(146.00K) (851.00K) (2.30M) (934.00K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
17.10M 17.05M 9.73M 2.99M
Minority Interest Expense
- - - -
-
Net Income
17.10M 17.05M 9.73M 2.99M
Net Income Growth
+88.48% -0.32% -42.91% -69.24%
Net Margin Growth
+13.13% +10.78% +5.28% +1.56%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
17.10M 17.05M 9.73M 2.99M
Preferred Dividends
- - - -
-
Net Income Available to Common
17.10M 17.05M 9.73M 2.99M
EPS (Basic)
0.4058 0.4432 0.2737 0.0937
EPS (Basic) Growth
+66.58% +9.22% -38.24% -65.77%
Basic Shares Outstanding
42.15M 38.47M 35.55M 31.94M
EPS (Diluted)
0.3967 0.4357 0.2693 0.0927
EPS (Diluted) Growth
+68.02% +9.83% -38.19% -65.58%
Diluted Shares Outstanding
43.12M 39.13M 36.14M 32.30M
EBITDA
26.05M 26.86M 15.00M 10.77M
EBITDA Growth
+120.33% +3.13% -44.17% -28.19%
EBITDA Margin
+19.99% +16.99% +8.14% +5.60%

Snapshot

Average Recommendation HOLD Average Target Price 2.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -1.42 Median PE on CY Estimate N/A
Year Ago Earnings 0.09 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 1
OVERWEIGHT 0 0 0
HOLD 1 1 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Overweight

Insider Actions for Zynex Inc - ZYXI

Date Name Shares Transaction Value
Mar 6, 2025 Daniel J. Moorhead CHIEF FINANCIAL OFFICER 10,050 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.15 per share 71,857.50
Mar 6, 2025 Daniel J. Moorhead CHIEF FINANCIAL OFFICER 10,645 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.23 per share 76,963.35
Mar 6, 2025 Daniel J. Moorhead CHIEF FINANCIAL OFFICER 68,855 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Zynex Inc in the News